<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05796492</url>
  </required_header>
  <id_info>
    <org_study_id>HS-22-00019</org_study_id>
    <nct_id>NCT05796492</nct_id>
  </id_info>
  <brief_title>Ultrasound Treatment on Wound Healing Time</brief_title>
  <acronym>GE-MTEC</acronym>
  <official_title>Fieldable Ultrasound Treatment to Enhance Inflammatory-Proliferative Phase Transition and Reduce Wound Healing Time</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Electric Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Electric Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, sham-controlled pilot study that will assess the safety and feasibility&#xD;
      of splenic focused pulsed ultrasound treatment on burn wound healing time in 24 subjects (12&#xD;
      active ultrasound and 12 sham controls).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Central Hypothesis underlying this study is that splenic ultrasound stimulation activates&#xD;
      the splenic anti-inflammatory pathway, thereby producing reduction in circulating macrophage&#xD;
      cytokine production, reduction of neutrophil invasiveness, or induction of phenotypic&#xD;
      transition in circulating immune cells (e.g., M1 to M2 transition in macrophages) in patients&#xD;
      with partial thickness wounds that cover &lt;20% body surface area.&#xD;
&#xD;
      Approximately 24 subjects will participate in this study. Male and female subjects of all&#xD;
      races and ethnicities will be recruited for study from the ethnically diverse patient&#xD;
      population of the LAC+USC Burn Center from the surrounding area.&#xD;
&#xD;
      Phase 0&#xD;
&#xD;
      Burn wound subjects will be screened and enrolled at the LAC+USC Burn Center located in Los&#xD;
      Angeles, California. No other sites, neither regional nor outside of the United States are&#xD;
      going to participate in enrollment of subjects.&#xD;
&#xD;
      A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to&#xD;
      selectively deliver pulsed ultrasound to the spleen.&#xD;
&#xD;
      12 months.&#xD;
&#xD;
      28 days or until healed (whichever comes first)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2023</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse device effects (ADEs)</measure>
    <time_frame>Days 1 -28</time_frame>
    <description>Review of anticipated device effects after splenic ultrasound insonification in subjects with partial thickness wounds that cover &lt;20% body surface area.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median time to re-epithelialization using advanced digital imaging</measure>
    <time_frame>28 days or until healed (whichever comes first)</time_frame>
    <description>Re-epithelialization measured by digital planimetry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in groups in pain measured visual analog scale, (VAS)</measure>
    <time_frame>Days 7, 14, 21 and 28</time_frame>
    <description>Pain, scale 0-10 with 10 being worst outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in groups in itch measured visual analog scale, (VAS)</measure>
    <time_frame>Days 7, 14, 21 and 28</time_frame>
    <description>Itch, scale 0-10 with 10 being worst outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in groups in non-invasive perfusion measured visual analog scale, (VAS)</measure>
    <time_frame>Days 7, 14, 21 and 28</time_frame>
    <description>Doppler perfusion, scale 0-10 with 10 being worst outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Referral to scar management specialist</measure>
    <time_frame>Days 7, 14, 21 and 28</time_frame>
    <description>Scar management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scar assessments using Patient and Observer Scar Assessment Scale (POSAS)</measure>
    <time_frame>Days 7, 14, 21 and 28</time_frame>
    <description>A 5 point score ranging from 1 (normal pigmentation, no itching) to 5 (worst imaginable scar or sensation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiplexed analysis of plasma levels of inflammatory cytokines</measure>
    <time_frame>Days 7, 14, 21 and 28</time_frame>
    <description>Plasma levels of inflammatory cytokines, lab range values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow cytometry analysis of phenotype of macrophage, neutrophil, and T lymphocyte populations</measure>
    <time_frame>Days 7, 14, 21 and 28</time_frame>
    <description>Phenotype of macrophage, neutrophil, and T lymphocyte, lab range values</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Burn Wound</condition>
  <condition>2nd Degree Burn of the Skin</condition>
  <arm_group>
    <arm_group_label>LOGIQ E10 Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The sham condition will consist of the ultrasound probe placed over the spleen with no energy applied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LOGIQ E10 ultrasound Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The intervention condition will receive 10 minutes of splenic ultrasound daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulsed splenic ultrasound</intervention_name>
    <description>A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to the spleen.</description>
    <arm_group_label>LOGIQ E10 ultrasound Active</arm_group_label>
    <other_name>Active ultrasound</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound probe (no energy applied)</intervention_name>
    <description>A General Electric LOGIQ E10 ultrasound probe will be placed over the spleen with no energy applied</description>
    <arm_group_label>LOGIQ E10 Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female aged 18 or older&#xD;
&#xD;
          -  Second-degree burn wounds of less than 20% total body surface area (TBSA)&#xD;
&#xD;
          -  No active wound infection at screening based on clinical criteria&#xD;
&#xD;
          -  Able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Wounds determined by study clinicians to be ineligible, including those that may&#xD;
             inhibit access to the spleen for the ultrasound procedure&#xD;
&#xD;
          -  Participating in another research study that may affect the conduct of results of this&#xD;
             study&#xD;
&#xD;
          -  BMI &gt; 30&#xD;
&#xD;
          -  Having or exhibiting any of the following:&#xD;
&#xD;
               -  Previous surgery of the spleen, esophagus, stomach, duodenum, or liver, including&#xD;
                  splenectomy&#xD;
&#xD;
               -  End stage renal disease and/or uremia&#xD;
&#xD;
               -  Active malignancy&#xD;
&#xD;
               -  Previous leukemia and/or lymphoma&#xD;
&#xD;
               -  Human immunodeficiency virus infection or AIDS&#xD;
&#xD;
               -  Rheumatoid arthritis or other immune-mediated diseases (e.g., inflammatory bowel&#xD;
                  disease&#xD;
&#xD;
               -  Arrythmias, including but not limited to, atrial fibrillation, atrial flutter,&#xD;
                  clinically significant bradycardia, ventricular arrhythmias, and A-V block&#xD;
&#xD;
               -  Implanted pacemaker or cardioverter/debribrillator&#xD;
&#xD;
               -  History of unstable angina, angioplasty or coronary arterial by-pass grafting&#xD;
                  surgery&#xD;
&#xD;
               -  History of stroke or TIA&#xD;
&#xD;
               -  Untreated thrombosis or bleeding disorders&#xD;
&#xD;
               -  Currently implanted vagus nerve stimulator&#xD;
&#xD;
               -  Currently implanted spinal cord stimulator or other chronically implanted&#xD;
                  electronic device&#xD;
&#xD;
          -  Receiving oral, topical, rectal, or parenteral corticosteroids in an unstable dose 4&#xD;
             weeks prior to baseline visit&#xD;
&#xD;
          -  Any immunosuppressive or cytotoxic medications&#xD;
&#xD;
          -  Clinically relevant history of alcohol or drug abuse as determined by the investigator&#xD;
             including:&#xD;
&#xD;
               -  alcohol consumption within 4 days of the baseline visit&#xD;
&#xD;
               -  tobacco or nicotine product use within the past 1 month&#xD;
&#xD;
               -  recreational drug use within the past 1 month&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Unable or unwilling to comply with study procedures&#xD;
&#xD;
          -  Have recently (within 3 months) been diagnosed with COVID, or have ever been diagnosed&#xD;
             with long COVID&#xD;
&#xD;
          -  Have an autoimmune disorder, such as, rheumatoid arthritis or lupus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Armstrong, DPM, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USC Limb Preservation Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elia Salazar Plascencia, Ed.D, MPH</last_name>
    <phone>(323) 442-4834</phone>
    <email>Elia.salazar@med.usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>LAC+USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Elia Salazar Plascencia</last_name>
    </contact>
    <contact_backup>
      <last_name>Jason Garcia</last_name>
    </contact_backup>
    <investigator>
      <last_name>David G Armstrong, DPM, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>August 22, 2022</study_first_submitted>
  <study_first_submitted_qc>March 30, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 30, 2023</last_update_submitted>
  <last_update_submitted_qc>March 30, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

